TORONTO, ONTARIO–(Marketwired – Jan. 16, 2015) – Arch Biopartners Inc (“Arch”) (CSE:ACH)(OTCBB:FOIFF) has received conditional approval from the TSX Venture Exchange (“TSXV”) for the listing of its common shares on the TSXV.
Press Releases
Arch Biopartners Announces Private Placement
TORONTO, ONTARIO–(Marketwired – Jan. 6, 2015) – Arch Biopartners Inc (“Arch or the “Company”) (CSE:ACH)(OTCBB:FOIFF) intends to complete a non-brokered private placement offering of up to 2,143,000 units priced at $0.35 per unit (the “Units”) for gross proceeds of up to $750,050 (the “Offering”).
Arch Biopartners Completes Clinical Development Plan for MetaMx
TORONTO, ONTARIO–(Marketwired – Nov. 26, 2014) – Arch Biopartners Inc (CSE:ACH)(OTCBB:FOIFF) has now completed a Clinical Development Plan (“CDP”) to prepare a human trial for MetaMx, the Company’s brain tumour targeting technology.
Arch Biopartners Introduces Metablok, a Novel Therapeutic Candidate for Blocking Sepsis, Cancer Metastasis
TORONTO, ONTARIO–(Marketwired – Oct. 15, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CSE:ACH)(OTCBB:FOIFF) announced today the introduction of Metablok, a new drug candidate in its development pipeline as a potential treatment for sepsis and cancer metastasis.
Arch Biopartners Appoints Adrian Haigh to Board of Directors
TORONTO, ONTARIO–(Marketwired – Aug. 21, 2014) – Arch Biopartners Inc (“Arch” or the “Company) (CSE:ACH)(OTCBB:FOIFF) announced today the board has appointed Adrian Haigh as an interim director.
Mr.
Arch Biopartners Hires d3 Medicine to Develop a Human Trial for Brain Tumor Targeting Technology
TORONTO, ONTARIO–(Marketwired – May 29, 2014) – Arch Biopartners Inc (Arch) or (the Company) (CSE:ACH)(OTCBB:FOIFF) announced today it has hired d3 Medicine to work as the Company’s new drug development team.
d3’s first task will be to design a Phase I/II human trial for MetaMx, the Company’s brain tumour targeting technology, in patients with malignant glioma.
Arch Biopartners Appoints Claude Allary to Board of Directors
TORONTO, ONTARIO–(Marketwired – April 17, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) announced today the board has appointed Claude Allary as an interim director.
Mr.
Arch Biopartners Enters Option to License University of Cincinnati Patent for Treating Bacterial Respiratory Infections
TORONTO, ONTARIO–(Marketwired – March 28, 2014) – Arch Biopartners Inc (Arch) or (the Company) (CSE:ACH)(OTCBB:FOIFF) announced today it has entered into a one year option agreement with the University of Cincinnati (UC) to exclusively license the commercial rights to a U.S.
Arch Biopartners Announcement
TORONTO, ONTARIO–(Marketwired – March 12, 2014) – With profound sadness, Arch Biopartners Inc. announces the passing of its Chairman, Jerry McElroy. The Board and management will miss his friendship, guidance and good judgment since the formation of the company.
Arch Biopartners Completes Private Placement and Receives NRC Funding
TORONTO, ONTARIO–(Marketwired – Feb. 25, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CSE:ACH)(OTCBB:FOIFF) announced today it has raised $228,900 via a non-brokered private placement of 817,500 Units at a price of $0.28 per Unit.